艾迪注射液联合营养支持对晚期胃癌患者生存质量及生存期的影响  

Clinical analysis of quality of life and survival time in 100 patients with advanced gastric cancer treated with Aidi injection and nutritional support

作　　者：周聆[1] 张为强[1] 

机构地区：[1]上海市北医院,上海200435

出　　处：《中医药导报》2014年第6期61-63,共3页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：上海市闸北区科委课题(20112Zd11)

摘　　要：目的:观察艾迪注射液联合营养支持治疗对晚期胃癌患者生存质量、生存期的影响。方法:将100例晚期胃癌患者按入组先后随机分为3组,A组对照组(艾迪治疗)33例;B组治疗组(艾迪+肠内营养)33例;C组治疗组(艾迪+肠外营养)34例。治疗前及治疗后分别检测各组的KPS评分、抗肿瘤疗效、相关脏器感染率、不良反应发生率及监测生存期等。结果:营养状况指标:A组治疗后上述指标变化差异无统计学意义(P>0.05)。B、C组均显著上升,差异有统计学意义(P<0.05)。B、C组之间差异无统计学意义(P<0.05)。免疫指标:A、C组治疗后上述指标变化差异无统计学意义(P<0.05)。B组上述指标均不等程度升高,差异有统计学意义(P<0.05)。B、C组之间差异有统计学意义(P<0.05)。疾病控制率(DCR):B、C组与A组比较,差异有统计学意义(P<0.05)。B、C组之间差异有统计学意义(P<0.05)。相关脏器感染率:B、C组与A组比较,差异有统计学意义(P<0.05)。B、C组之间差异有统计学意义(P<0.05)。不良反应发生率:A组无不良反应发生。B、C组之间差异有统计学意义(P<0.05)。100例生存期情况:各组间差异无统计学意义(P<0.05)。结论:艾迪注射液联合营养支持尤其肠内营养途径能改善晚期胃癌患者的营养状态、增强免疫力,降低感染率,控制肿瘤病灶进展,提高患者的生存质量,但对生存期无明显影响。Objective： To investigate the effect of Aidi injection and nutritional support on the quality of life and survival time of patients with advanced gastric cancer. Method： The 60 patients with advanced gastric cancer were randomly divided into 3 groups, 33 cases in group A （the control group treated with Aidi）, 33 cases in group B （treated with Aidi and enteral nutrition） and 34 cases in group C （treated with Aidi and parenteral nutrition）. Before and after the treatment, KPS, anti-tumor efficiency, infection rate, adverse reactions and life time were evaluated. Results： Nutritional status indicators： group A showed no changes after treatment （P〉0.05）, but group B and C were significantly increased （P〈0.05）; There was no significant difference between groups B and C （P〉0.05）. Immune index： group A and C showed no changes after treatment （P〉0.05） ; the immune index in group B improved, with significant difference （P〈0.05）; There was significant difference between groups B and C （P〈 0.05）. Disease control rate （DCR）： Group B and C showed statistically significant lower DCR than group A （P〈0.05）, and there was significant difference between groups B and C （P〈0.05）. Incidence of adverse reactions： Group B and C showed statistically significant lower incidence of adverse reactions than group A （P〈0.05）, and there was significant difference between groups B and C （P〈0.05）. Survival time： there was no significant difference between the three groups （P〉0.05）. Conclusion： Aidi injection combined nutritional support, especially enteral nutrition, can improve the nutritional status of patients with advanced gastric cancer, enhance immunity, reduce infection rates, control the progression and improve quality of life, but with no effect on survival time.

关 键 词：艾迪注射液 营养支持 晚期胃癌 生存质量 生存期 

分 类 号：R273[医药卫生—中西医结合]